Purpose: A high number of adverse drug reactions (ADRs), mainly caused by drug-drug interactions (DDIs), occur in neurological wards and few data are available about incidence and prevalence of DDIs in this context. This study investigated-(1) the prevalence of drug-drug and drug-disease interactions in patients admitted to a neurological unit in Italy, (2) the risk factors for DDIs, and (3) the diseases and the drug classes mostly involved in drug-drug and drug-disease interactions. Methods: For 2 months, we performed a retrospective, observational study in the neurological unit of St Bassiano Hospital, enrolling 79 patients who received a drug prescription at discharge. Results: About half of the patients were discharged with 5 or more prescribed drugs, and 72% of patients showed potential, clinically relevant DDIs. Linear correlations were observed between age and number of prescribed drugs (P < .01) and between age and number of interactions (P < .01). The number of prescribed drugs was associated with the number of detected DDIs (P < .01). The application of drug interaction alerts and the use of medication inappropriateness criteria (ie, Beers criteria) were not satisfactory in choosing the best therapy for each patient. Therefore, multidisciplinary discussions of each clinical case was required. Conclusion: The study demonstrated that the neurological patient, especially if elderly, has a high risk of DDI and ADRs and that many of these can be avoided by case discussion in multidisciplinary team meetings, in which the presence of a dedicated clinical pharmacist is crucial.
Introduction
Adverse drug reactions (ADRs) are among the leading causes of mortality, morbidity, and prolonged inpatient treatment. 1, 2 The magnitude of ADRs and the burden they place on healthcare system are considerable. [3] [4] [5] [6] [7] However, the public health problem they represent is preventable, if we take into account that an important cause of ADRs is drug-drug interactions (DDIs). 8, 9 A recent analysis of type, occurrence, and frequency of drug-related problems (DRPs) in different medical departments (urology, neurology, and gastroenterology) underlined that the most pronounced DRPs found were DDIs. 10 In the last decades, various criteria have been developed to identify inappropriate drug therapies in geriatrics. Beers, a geriatrician, first created the Beers criteria in 1991, through a consensus panel of experts using the Delphi method. The criteria were originally published in the Archives of Internal Medicine in 1991 and were updated in 1997, 2003, 2012, and 2015. 11 "The Beers Criteria for Potentially Inappropriate Medication Use in Older Adults," commonly called the Beers list, is a guideline for health-care professionals to help improve the safety of prescribing medications for older adults. It emphasizes deprescribing unnecessary medications, thereby reducing the problems of high-risk-benefit ratio, polypharmacy, DDIs, and ADRs. 11 Other geriatric inappropriate prescribing criteria have been devised and validated; examples include Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START) for detection of potential errors of prescribing commission and omission.
Hospitalized patients are more likely to be affected by these DDIs because of severe and multiple illnesses, chronic therapeutic regimens, polytherapy, and frequent modification in therapy. 13 Although a substantial body of the literature on ADRs caused by DDIs exists, it is difficult to accurately estimate their incidence, mainly because of different study designs, populations, frequency measures, and classification systems. [14] [15] [16] [17] [18] [19] The incidence of potential DDIs is close to 40% in patients taking 5 drugs and exceeds 80% in patients taking 7 or more medications. 20 A study conducted in Switzerland reported that 56.2% of patients were exposed to 1 or more severe or moderate potential DDI in the internal medicine ward and that 47% of all severe and moderate DDIs at hospital discharge were created during hospitalization. 21 Pasina et al demonstrated that among 2314 discharged patients, 1598 (69.1%) were exposed to at least 1 potential DDI, and 1561 (24.2%) to at least 1 potentially severe DDI. 22 The American Geriatrics Society identified the evaluation of drug-drug and drug-disease interactions as essential for the optimal care of older adults with multiple diseases. 23 Potential DDIs require intervention protocols including administration of appropriate alternative medicine, dose adjustment, and monitoring of clinical signs and symptoms by healthcare professionals to minimize possible ADRs. [24] [25] [26] Clinical pharmacist-led services for improving medication safety in hospitals and in the community have been shown to improve both patient-and cost-related outcomes. 27 These services have been well described both in ambulatory and hospital settings, especially in internal medicine but also for intensive care, surgery, psychiatry, and geriatrics. 28 Similarly to the departments of internal medicine, a high number of ADRs also occur in the neurological units. 29 Due to the old age of the treated patients, comorbidities and especially cardiovascular comedications represent an additional risk factor for ADRs. 29 Zaal et al demonstrated in an observational prospective follow-up study that most of the DRPs identified by a clinical pharmacist were not detected in daily clinical practice by physicians and that the clinical pharmacist effectively contributes to reducing DRPs. 30 The present study was designed to (1) investigate the prevalence of drug-drug and drug-disease interactions in patients admitted to the neurology ward in 1 Italian hospital, (2) underline the risk factors for drug interactions, and (3) identify the drug classes, prescribed in the neurological contest, which are mostly involved in drug interactions. These evaluations were conducted with the support of clinical pharmacists during drug management activities in a neurology unit.
Methods

Design of the Study
The study was conducted in a neurology unit of an over 500-bed hospital (St Bassiano Hospital, Bassano del Grappa, Italy). This is a retrospective observational study, which involved the collection of clinical and therapeutic data of patients admitted and discharged from the neurology unit from October 2014 to December 2014 (2 months). Clinical and demographic information was collected from the clinical records. All enrolled patients signed an informed consent form. Patients were considered eligible when they were inpatients for more than 24 hours and they received at least 2 drugs. Demographic informations and prescribed medications with a schedule of administration were recorded in a document designed for this purpose. A clinical pharmacist supported the neurologists by identifying and recording the potential DDI; the primary source to identify drug-drug and drug-disease interactions was the online tool "Drug Interactions Checker." 31 This drug information database is powered by 4 independent leading medical information suppliers-Wolters Kluwer Health, American Society of Health System Pharmacists, Cerner Multum, and Micromedex from Truven Health. The software provided information such as drug class, type, severity, and reliability of interaction, management, and intervention. Drug-drug interactions are categorized in minor, moderate, and severe on the basis of their intensity. Minor drug interactions do not result in any significant troublesome outcomes. Management of these types of interactions is usually not required. Moderate drug interactions could result in a worsening of the clinical condition of the patient. A treatment to manage such type of interactions could be considered. Severe drug interactions could lead to lifethreatening conditions, and therefore, it is essential to deal with them as soon as they are identified. The prevalence of drugdrug/drug-disease interactions was estimated using the following formula-frequency of DDIs ¼ (number of potential DDIs/ number of patients) Â 100.
Statistical Analysis
Descriptive and inferential statistical analysis was performed using SigmaPlot version 12. Descriptive statistics of the patients are summarized in Table 1 . The relationship between age, number of drug interactions, and number of prescribed drugs was calculated using the Pearson product-moment correlation test. Difference in means between groups was assessed by t test, whereas differences in medians were tested using the Wilcoxon rank sum test. Data were considered as statistically significant when P < .05.
Results
A total of 79 patient case records were reviewed in the neurology unit during the study. Forty-two (53%) patients were males and 37 (47%) females. The mean age of patients was 60 years, ranging from 16 to 91 years, with a median value of 65 years. The demographic characteristics of patients are presented in Table 1 . The principal diagnosis of the studied population was stroke (21.52%). The neurologic diseases leading to inpatient admission are listed in Table 2 . Table 2 shows the median number of prescribed drugs, number of comorbidities, and median number of interactions for each type of diagnosis. Due to the small number of patients enrolled, subgroup analysis was not considered.
Forty-one (51%) patients were discharged with a therapy consisting of 5 or more drugs (Table 1) , and this polytherapy could be partially justified by important comorbidities (Table 1 ). In the subgroup of stroke patients, the polytherapy (5 or more drugs) was higher (56%). The need to control cerebro/cardiovascular risk factors justified the polytherapy while it enhanced the risk of DDIs. We observed a linear statistically significant correlation between age and number of prescribed drugs (R ¼ 0.394; P < .01; Figure 1 ) and a similar statistically significant correlation between age and number of interactions (R ¼ .329; P < .01; Figure 2 ). As expected, the study demonstrated a statistically significant correlation between the number of prescribed drugs and the number of detected interactions (R ¼ 0.816, P < .01; Figure 3) . A total of 57 (72%) patients showed potential drug interactions (Table 3 ). The mean number of interactions per patient was 4.7 (7.2) (mean [standard deviation]). One hundred seven (30%) of 373 potential drug interactions were related to drug-disease interactions while DDIs accounted for the remaining 70% (n ¼ 266; Table 3 ). Most of the potential drug-disease interactions had a moderate (45.8%) to severe (54.2%) clinical relevance, whereas most of the DDIs (78.6%) had a moderate clinical impact (Table 3) . Most of the diseases involved in drug interactions were either high incidence/prevalence pathologies, such as hypertension, renal failure, dyslipidemia, and diabetes (Table 4) , which also represented the principal comorbidities of these patients (Table 1) . Concerning the comorbidities, we performed additional statistical analysis comparing patients presenting or not the 3 most frequent comorbid conditions: high blood pressure, dyslipidemia, and diabetes. We observed that patients with high blood pressure, which was the most frequent comorbidity, were significantly older, received a higher number of 
Descriptive data about the number and percentage of patients for each type of neurological disease that caused the in-patient admission. b For each diagnosis, it is reported the median age of patients, the median number of drugs prescribed, and comorbidities and interactions. Figure 1 . Correlation between age and number of drugs. The correlation between age and the number of drugs prescribed at patients' discharge has been assessed using the Pearson product-moment correlation method (R ¼ 0.394; P .01; n ¼ 79).
drugs, and had a higher risk of developing interactions (especially drug-disease interactions). Results are reported in Table 5 .
Having dyslipidemia, the second most frequent comorbidity, is not associated with a higher number of prescriptions or interactions. Finally, diabetes, which ranks third among comorbidities, is associated with a higher number of prescriptions and interactions but not with being older.
The most implicated drugs in drug interactions were-drugs for the treatment of cardiovascular and cerebrovascular diseases, antidiabetics, proton pumps inhibitors, benzodiazepines, and antiepileptic drugs (Table 6) .
Concerning the type of interaction identified, a high number of simultaneously prescribed drugs is related to drug-drug and drugs-disease interactions (Figure 4 ). On the other hand, an older age correlated with the number of both types of interactions, thus showing a correlation between age, polypharmacy, and number of potential DDIs ( Figure 5 ). In this scenario, the most complex clinical cases need to be discussed in a multidisciplinary team formed by neurologists, nurses, and clinical pharmacists with the aim to improve clinical practice. For example, a 51-year-old man with a diagnosis of ischemic stroke and a high number of comorbidities (hypertension, dyslipidemia, insulin-dependent diabetes mellitus, partial epilepsy with secondary generalization, cardiomyopathy-aortic bioprosthesis replacement in the past, and obesity) was discharged after a 12-day hospitalization. This patient received a polytherapy prescription (17 medications) characterized by a complex medication regimen that could generate a relevant number of drug-drug and drugdisease interactions (39 potential drug interactions were identified; Supplemental Table 1 ). The correlation between the number of drugs prescribed at patients' discharge and the number of possible interactions derived from these prescriptions has been assessed using the Pearson product-moment correlation method (R ¼ .816; P .01). The interactions considered in this analysis comprehend both drug-drug interactions and drug-disease interactions (n ¼ 79). 
Discussion
Our study demonstrated that a high prevalence of potential DDIs in neurological patients at hospital discharge exists, and these data are similar in the internal medicine ward. 21, 22 Like Pasina et al, we showed that about 70% of discharged patients were exposed to at least 1 potential DDI.
The study demonstrated a significant correlation between age and number of prescribed drugs, as well as a similar statistically significant correlation between age and number of interactions. Therefore, in the neurology unit, the daily application of Beers and START/STOPP criteria is useful to minimize inappropriate prescriptions in older neurological patients. Moreover, the study showed that, in a neurology unit, the evaluation of drug-drug and drug-disease interactions is essential for the optimal care of people affected by multiple diseases, as argued by the American Geriatrics Society. 11, 12, 23 The most implicated drugs in drug interactions were-drugs for the treatment of cardiovascular and cerebrovascular diseases (the most prescribed drugs in neurological unit), antidiabetics, proton pumps inhibitors, benzodiazepines, and antiepileptic drugs. The majority of patients admitted in the neurology unit of St Bassiano Hospital, who had been diagnosed with 1 neurological disease, had comorbidities. The study permitted to observe that neurologic patients need personalized therapies, with evaluation of age and comorbidities, that were correlated to a higher number of drugs and a higher risk of developing interactions.
Furthermore, as shown in the clinical case (Supplemental Table 1 ), the involvement of the clinical pharmacist in the neurology unit team was essential (1) to evaluate the appropriateness of the prescribed medications (eg, detection of inappropriate allopurinol prescription in asymptomatic hyperuricemia), (2) to identify clinically significant potential DDIs and support physician in managing these interactions, (3) to define the therapeutic adherence, and (4) to promote the prescription of different pharmaceutical formulations and/or to simplify regimen of drugs, in order to increase adherence and reduce DRPs. 32 The involvement of a clinical pharmacist in the neurology unit team was essential for the identification and the analysis of drug interactions in this observational study. Therefore, it is fundamental that the pharmacist is fully integrated in the team to appropriately manage the DDIs by checking-the specific risk factors, the dose of each drug used, the route of administration, the therapeutic index, the duration of therapy, and the existence of ADR reports. In this scenario, the multidisciplinary management of the patient becomes increasingly important.
Conclusion
The neurological patient has a high risk of interactions and ADRs, considering the number and type of concomitant medications prescribed. The ADRs determine increased clinical risk to the patient, as well as increased hospital admissions/ prolongation of hospitalization with the relative increase of costs for a public national health system like an Italian. Drug interactions are the main cause of adverse reactions. Some interactions may be avoided by a "medication review" for each patient to improve the quality of prescribing and to prevent adverse drug events. A close collaboration between physicians and pharmacists seems to be a good strategy to reach this goal. The figure of the pharmacist in the departmental team is dedicated to activities of training and information provision to the Figure 4 . Correlation between the number of drugs and the type of interactions. The correlation between the number of drugs prescribed at patients' discharge and the type of possible interactions derived from these prescriptions has been assessed using the Pearson product-moment correlation method. The interactions considered in this analysis were drug-disease interactions (panel A; R ¼ .667; P < .01) and drug-drug interactions (panel B; R ¼ .823; P < .01; n ¼ 79). Figure 5 . Correlation between the age and the type of interactions. The correlation between the age of patients and the type of possible interactions derived from these prescriptions has been assessed using the Pearson product-moment correlation method. The interactions considered in this analysis were drug-disease interactions (panel A; R ¼ 0.321; P .01) and drug-drug interactions (panel B; R ¼ 0.310; P .01; n ¼ 79).
patient on the proper use of the drug/ADR analysis and compliance, as well as to support the clinical and nursing staff. In every hospital, the pharmacist should be involved in multidisciplinary teams to detect DRPs (ie, drug interactions, ADRs), and this practice should be an integral part of clinical activity, in order to improve both patient-and cost-related outcomes, and data that have already been demonstrated by several studies. 27 
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